Notice seeking comments on proposed coastwise use of foreign-built small passenger vessel M/V ENDEAVOUR
AI-generated summary for informational purposes only. Not legal advice. See the original source for the authoritative text.
This notice asks the public to comment on whether a foreign-built small passenger vessel, the M/V ENDEAVOUR, should be allowed to operate in U.S. coastwise trade. MARAD will use the comments to decide whether the proposed use would hurt U.S. vessel builders or businesses that rely on U.S.-built passenger vessels. Companies in passenger vessel services, U.S. shipbuilders, and other coastal trade operators may want to review the request and submit evidence if they think the change would create an unfair competitive impact. Comments are due by June 1, 2026, and submissions will be public unless filed as confidential commercial information.
AI-generated summary. May contain errors. Refer to official sources for legal decisions.
Key Changes
- MARAD is seeking public comments on a request to use the M/V ENDEAVOUR in U.S. coastwise trade.
- The agency will assess whether the proposed use would negatively affect U.S. vessel builders or coastwise businesses that use U.S.-built vessels.
- Comments must be submitted by June 1, 2026, and can be filed publicly or as confidential commercial information.
Obligations
What this law requires
Interested parties who wish to influence MARAD’s determination should submit comments on whether the proposed use of the M/V ENDEAVOUR would have an undue adverse effect on U.S. vessel builders or U.S. coastwise trade businesses that use U.S.-built vessels, and should support their comments with documentation.
Comment submissions must identify the DOT docket number MARAD-2026-0662 and the agency name.
Comments must be written in English.
If submitting by mail or hand delivery, commenters should include the DOT docket number, name, mailing address, and an email address or telephone number so MARAD can contact them if needed.
If a submitter wants MARAD to treat a comment as commercially confidential, the submitter must email it to [email protected] with the subject line 'Contains Confidential Commercial Information' or 'Contains CCI' and specify the basis for confidential treatment, identifying the CCI portions.